SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on March 20, 2003; DOI 10.1182/blood-2002-11-3527. This Article Full Text (PDF) All Versions of this Article: 2002-11-3527v1 102/2/462    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Delaunay, J. Articles by Dombret, H. Search for Related Content PubMed PubMed Citation Articles by Delaunay, J. Articles by Dombret, H. Social Bookmarking                   What's this? Submitted November 20, 2002 Accepted March 8, 2003 Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML intergroup Jacques Delaunay, Norbert Vey, Thierry Leblanc, Pierre Fenaux, Francoise Rigal-Huguet, Francis Witz, Thierry Lamy, Anne Auvrignon, Didier Blaise, Arnaud Pigneux, Francine Mugneret, Christian Bastard, Nicole Dastugue, Jacqueline Van den Akker, Denis Fiere, Josy Reiffers, Sylvie Castaigne, Guy Leverger, Jean-Luc Harousseau, and Herve Dombret* Department of Hematology, Hopital Saint-Louis, Paris, France Department of Hematology, Institut Paoli-Calmettes, Marseille, France Department of Hematology, Hopital Claude Huriez, Lille, France Department of Hematology, Hopital Purpan, Toulouse, France Department of Hematology, Hopital Brabois, Nancy, France Department of Hematology, Centre Hospitalier Pontchaillou, Rennes, France Department of Hematology, Hopital Trousseau, Paris, France Department of Hematology, Hopital du Haut-Leveque, Pessac, France Department of Hematology, Hopital du Bocage, Dijon, France Department of Hematology, Centre Henri Becquerel, Rouen, France Department of Hematology, Hopital Saint-Antoine, Paris, France Department of Hematology, Hopital Edouard Herriot, Lyon, France Department of Hematology, Hopital Andre Mignot, Versailles, France Department of Hematology, Hotel-Dieu, Nantes, France * Corresponding author; email: herve.dombret{at}sls.ap-hop-paris.fr. Acute myeloid leukemias carrying inv(16)/t(16;16) chromosomal abnormalities are associated with a good prognosis. However, studies of this AML subtype have been hampered by the few number of patients reported, frequently collectively considered with those with AML carrying the t(8;21) translocation. We performed a retrospective study in 110 patients with inv(16)/t(16;16) AML (median age, 34 years) prospectively enrolled in six trials conducted in France between 1987 and 1998, with the aim to investigate prognostic factors for CR achievement and outcome of CR patients in this AML subtype. CR rate was 93%. Bad-prognosis factors for CR achievement were higher WBC and lower platelet count (optimal cutpoints at 120 and 30 G/L, respectively). At 3 years, estimated overall survival, DFS, and cumulative incidence of relapse were 58%, 48%, and 42%, respectively. In multivariate analysis: 1) advanced age (optimal cutpoint, 35 years) was the only factor for shorter DFS; 2) advanced age and low platelet count were the two factors for shorter survival of CR patients. Outcome of CR patients: 1) was not influenced by WBC and cytogenetic findings; 2) was similar among patients allocated to receive allogeneic transplantation, high-dose, or intermediate-dose cytarabine. Interestingly, advanced age was associated with a trend for more frequent additional chromosome abnormalities and predictive of higher cumulative incidence of relapse rather than death in CR1. These results markedly contrast with those reported in patients with t(8;21) AML in whom WBC, and not age, was the main high-risk factor for relapse, DFS, and survival. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Prebet, N. Boissel, S. Reutenauer, X. Thomas, J. Delaunay, J.-Y. Cahn, A. Pigneux, B. Quesnel, F. Witz, S. Thepot, et al. Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup J. Clin. Oncol., October 1, 2009; 27(28): 4747 - 4753. [Abstract] [Full Text] [PDF] T. Clozel, A. Renneville, M. Venot, C. Gardin, C. Kelaidi, G. Leroux, V. Eclache, C. Preudhomme, P. Fenaux, and L. Ades Slow relapse in acute myeloid leukemia with inv(16) or t(16;16) Haematologica, October 1, 2009; 94(10): 1466 - 1467. [Full Text] [PDF] J. Krauter, K. Wagner, I. Schafer, R. Marschalek, C. Meyer, G. Heil, M. Schaich, G. Ehninger, D. Niederwieser, R. Krahl, et al. Prognostic Factors in Adult Patients up to 60 Years Old With Acute Myeloid Leukemia and Translocations of Chromosome Band 11q23: Individual Patient Data-Based Meta-Analysis of the German Acute Myeloid Leukemia Intergroup J. Clin. Oncol., June 20, 2009; 27(18): 3000 - 3006. [Abstract] [Full Text] [PDF] J. Koreth, R. Schlenk, K. J. Kopecky, S. Honda, J. Sierra, B. J. Djulbegovic, M. Wadleigh, D. J. DeAngelo, R. M. Stone, H. Sakamaki, et al. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Systematic Review and Meta-analysis of Prospective Clinical Trials JAMA, June 10, 2009; 301(22): 2349 - 2361. [Abstract] [Full Text] [PDF] Y. Kuwatsuka, K. Miyamura, R. Suzuki, M. Kasai, A. Maruta, H. Ogawa, R. Tanosaki, S. Takahashi, K. Koda, K. Yago, et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes Blood, February 26, 2009; 113(9): 2096 - 2103. [Abstract] [Full Text] [PDF] L. Maurillo, F. Buccisano, M. I. Del Principe, G. Del Poeta, A. Spagnoli, P. Panetta, E. Ammatuna, B. Neri, L. Ottaviani, C. Sarlo, et al. Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia J. Clin. Oncol., October 20, 2008; 26(30): 4944 - 4951. [Abstract] [Full Text] [PDF] N.-C. Gorin, M. Labopin, F. Frassoni, N. Milpied, M. Attal, D. Blaise, G. Meloni, A. P. Iori, M. Michallet, R. Willemze, et al. Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation J. Clin. Oncol., July 1, 2008; 26(19): 3183 - 3188. [Abstract] [Full Text] [PDF] D. Messerer, J. Engel, J. Hasford, M. Schaich, G. Ehninger, C. Sauerland, T. Buchner, A. Schumacher, R. Krahl, D. Niederwieser, et al. Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia Haematologica, June 1, 2008; 93(6): 826 - 833. [Abstract] [Full Text] [PDF] R. F. Schlenk, K. Dohner, J. Krauter, S. Frohling, A. Corbacioglu, L. Bullinger, M. Habdank, D. Spath, M. Morgan, A. Benner, et al. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia N. Engl. J. Med., May 1, 2008; 358(18): 1909 - 1918. [Abstract] [Full Text] [PDF] B. Falini, I. Nicoletti, M. F. Martelli, and C. Mecucci Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features Blood, February 1, 2007; 109(3): 874 - 885. [Abstract] [Full Text] [PDF] C. D. Bloomfield, K. Mrozek, and M. A. Caligiuri Cancer and Leukemia Group B Leukemia Correlative Science Committee: Major Accomplishments and Future Directions. Clin. Cancer Res., June 1, 2006; 12(11): 3564s - 3571s. [Abstract] [Full Text] [PDF] R. Cairoli, A. Beghini, G. Grillo, G. Nadali, F. Elice, C. B. Ripamonti, P. Colapietro, M. Nichelatti, L. Pezzetti, M. Lunghi, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study Blood, May 1, 2006; 107(9): 3463 - 3468. [Abstract] [Full Text] [PDF] K. Mrozek and C. D. Bloomfield Chromosome Aberrations, Gene Mutations and Expression Changes, and Prognosis in Adult Acute Myeloid Leukemia Hematology, January 1, 2006; 2006(1): 169 - 177. [Abstract] [Full Text] [PDF] K. Dohner, R. F. Schlenk, M. Habdank, C. Scholl, F. G. Rucker, A. Corbacioglu, L. Bullinger, S. Frohling, H. Dohner, and for the AML Study Group (AMLSG) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations Blood, December 1, 2005; 106(12): 3740 - 3746. [Abstract] [Full Text] [PDF] G. Marcucci, K. Mrozek, A. S. Ruppert, K. Maharry, J. E. Kolitz, J. O. Moore, R. J. Mayer, M. J. Pettenati, B. L. Powell, C. G. Edwards, et al. Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study J. Clin. Oncol., August 20, 2005; 23(24): 5705 - 5717. [Abstract] [Full Text] [PDF] R.F. Schlenk, A. Benner, J. Krauter, T. Buchner, C. Sauerland, G. Ehninger, M. Schaich, B. Mohr, D. Niederwieser, R. Krahl, et al. Individual Patient Data-Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup J. Clin. Oncol., September 15, 2004; 22(18): 3741 - 3750. [Abstract] [Full Text] [PDF] C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer Childhood and Adolescent Lymphoid and Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 118 - 145. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020